Summary by Moomoo AI
Avenue Therapeutics, a pharmaceutical company, has been informed by the Division of Corporation Finance Office of Life Sciences that the United States Securities and Exchange Commission (SEC) will not review its Registration Statement on Form S-3, which was filed on January 24, 2024. The SEC's communication, dated January 29, 2024, was addressed to Alix MacLean, CEO of Avenue Therapeutics, and highlighted that the responsibility for the accuracy and adequacy of disclosures lies with the company and its management. The SEC also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Avenue Therapeutics has been directed to contact Tamika Sheppard at the SEC with any further questions.